Log In
Forgot username? Forgot password? New User? Sign Up Free
SCCM is performing maintenance on its websites. For the best browsing experience, please use Microsoft Edge or Safari. Those using Chrome or Firefox may experience access issues at this time.
Upcoming Maintenance October 29 – November 5 SCCM websites and systems will be unavailable beginning at 5:30 p.m. Central Time on October 29, 2024, as SCCM performs major updates to its digital infrastructure to better serve members. Any website that requires an SCCM Customer ID and password to log in will be unavailable until November 5, 2024. SCCM Customer Service and Staff will have limited capabilities, and response times will be longer during this time.
Tag Search
Clazakizumab is a monoclonal antibody against human interleukin-6 that may benefit patients hospitalized with severe or critical COVID-19 accompanied by hyperinflammation. Although not yet FDA approved, clinical trials are underway worldwide. Samantha Gambles Farr, MSN, NP-C, CCRN, RNFA, is joined by Bonnie E. Lonze, MD, PhD, to discuss the article, “A Randomized Double-Blinded Placebo Controlled Trial of Clazakizumab for the Treatment of COVID-19 Pneumonia With Hyperinflammation.”